ArticleArthritis & rheumatology (Hoboken, N.J.)2022

Rituximab versus cyclophosphamide for remission induction in active, severe antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Chung et al.

Siddharth Jain et al.PubMed ↗Publisher ↗

No numbers read from the abstract.